Nisa Investment Advisors
JANX icon

Nisa Investment Advisors’s Janux Therapeutics JANX Stock Holding History

Nisa Investment Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.9K Buy
3,967
+1,577
+66% +$22.8K ﹤0.01% 1776
2026
Q1 		$33.2K Buy
2,390
+970
+68% +$13.3K ﹤0.01% 1842
2025
Q4 		$19.6K Sell
1,420
-390
-22% -$9.17K ﹤0.01% 1951
2025
Q3 		$44.2K Buy
1,810
+40
+2% +$974 ﹤0.01% 1660
2025
Q2 		$40.9K Hold
1,770
– – ﹤0.01% 1646
2025
Q1 		$47.8K Sell
1,770
-10,097
-85% -$381K ﹤0.01% 1601
2024
Q4 		$635K Sell
11,867
-8,476
-42% -$448K ﹤0.01% 996
2024
Q3 		$924K Buy
20,343
+17,592
+639% +$765K 0.01% 877
2024
Q2 		$115K Buy
2,751
+18
+0.7% +$845 ﹤0.01% 1438
2024
Q1 		$103K Buy
2,733
+23
+0.8% +$501 ﹤0.01% 1455
2023
Q4 		$29.1K Buy
2,710
+2,685
+10,740% +$23.2K ﹤0.01% 1764
2023
Q3 		$252 Buy
+25
New +$288 ﹤0.01% 2636

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Nisa Investment Advisors's JANX Position: Q2 2026 in Review

Nisa Investment Advisors increased its Janux Therapeutics (JANX) stake by 66% in Q2 2026, buying an estimated $22.8K and bringing the position to 3,967 shares worth $60.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

Nisa Investment Advisors first reported a position in JANX in Q3 2023 and has held it in 12 quarters since. The position peaked at $924K in Q3 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Nisa Investment Advisors held 3,967 shares of Janux Therapeutics worth $60.9K as of Q2 2026.
  • Nisa Investment Advisors bought 1,577 Janux Therapeutics shares in Q2 2026, an estimated $22.8K.
  • Janux Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1776 holding.
  • Nisa Investment Advisors first reported a position in Janux Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Nisa Investment Advisors's Janux Therapeutics position peaked at $924K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.